As of May 23, 2025, Vistagen Therapeutics Inc (VTGN) reports a ROE (Return on Equity) of -25.69%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Vistagen Therapeutics Inc's ROE (Return on Equity)
Over recent years, Vistagen Therapeutics Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-03-31 | -25.69% |
| 2023-03-31 | -489.67% |
| 2022-03-31 | -73.82% |
| 2021-03-31 | -19.49% |
| 2020-03-31 | 364.39% |
This slight downward trend highlights how Vistagen Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Vistagen Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Vistagen Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Vistagen Therapeutics Inc (VTGN) | -25.69% |
| Trevena Inc (TRVN) | 526.17% |
| Abbvie Inc (ABBV) | 128.66% |
| Amgen Inc (AMGN) | 69.59% |
| Regeneron Pharmaceuticals Inc (REGN) | 15.03% |
| Galera Therapeutics Inc (GRTX) | 13.19% |
Compared to its competitors, Vistagen Therapeutics Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.